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Stroke is one of the leading causes of death and disability worldwide, and ischemic
stroke accounts for approximately 87% of cases. Improving post-stroke recovery
is a major challenge in stroke treatment. Accumulated evidence indicates that the
apelinergic system, consisting of apelin and apelin receptor (APLNR), is temporally
dysregulated in ischemic stroke. Moreover, the apelinergic system plays a pivotal role
in post-stroke recovery by inhibiting neuronal apoptosis and facilitating angiogenesis
through various molecular pathways. In this review article, we summarize the temporal
expression of apelin and APLNR in ischemic stroke and the mechanisms of their
dysregulation. In addition, the protective role of the apelinergic system in ischemic stroke
and the underlying mechanisms of its protective effects are discussed. Furthermore,
critical issues in activating the apelinergic system as a potential therapy will also be
discussed. The aim of this review article is to shed light on exploiting the activation of
the apelinergic system to treat ischemic stroke.
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INTRODUCTION
Stroke is one of the leading causes of death and disability worldwide and the majority
of cases are ischemic stroke. To improve recovery and reduce disability, novel therapeutic
approaches need to be developed, as current treatments are only limited to thrombolytic
therapy within an extremely narrow time window (Craig and Housley, 2016). A growing body
of evidence indicates that the apelinergic system, consisting of apelin and apelin receptor
(APLNR), is implicated in ischemic stroke. First, Hata et al. (2007, 2011) showed that a
single-nucleotide polymorphism (SNP, rs9943582) in APLNR is significantly associated with the
increased risk of ischemic stroke in human. Moreover, the expression of apelin and APLNR
Abbreviations:ACE2, angiotensin-converting enzyme 2; AKT, serine/threonine kinase; APLN, apelin; APLNR, apelin
receptor; ATF4, activating transcription factor 4; CAT, catalase; ER, endoplasmic reticulum; ERK, extracellular
signal-regulated kinase; GSH-Px, glutathione peroxidase; HIF-1α, hypoxia inducible factor 1 alpha; HREs, hypoxia
response elements; ICAM-1, intercellular adhesion molecule 1; IL-1β, interleukin 1 beta; mTOR, mechanistic
target of rapamycin; NEP, metalloprotease; p38-MAPK, p38 mitogen-activated protein kinase; PCSK3, proprotein
convertase subtilisin/kexin 3; PI3K, phosphatidyl Inositol 3-kinase; PLCβ-PKC, phospholipase C beta-protein kinase
C; ROS, reactive oxygen species; SOD, superoxide dismutase; SP1, Sp1 transcription factor; STAT3, signal transducer
and activator of transcription 3; TNF-α, tumor necrosis factor alpha; USF1/USF2, upstream transcription factor
1/upstream transcription factor 2; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth
factor receptor 2.
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is temporally dysregulated during different phases of ischemic
stroke. Importantly, a number of studies showed that the
apelinergic system plays a pivotal role in protecting cells from
ischemic stroke-induced apoptosis and improving behavioral
performance. The aforementioned evidence indicates that the
apelinergic system might be a potential target for novel
treatments. Therefore, we summarize the temporal expression of
apelin and APLNR in ischemic stroke, the mechanisms of their
dysregulation, the protective effect of the apelinergic system on
ischemic stroke and the underlying mechanisms of its protective
effect. In addition, we also discuss critical issues that may affect
strategies for activating the apelinergic system as a potential
therapy.
OVERVIEW OF ISCHEMIC STROKE
Epidemiology and Prevalence of Ischemic
Stroke
Stroke, caused by the disturbance of blood supply to the brain,
is the second leading cause of death and the third leading cause
of disability worldwide (Wang et al., 2012). In the United States,
stroke is the leading cause of long-term disability, including
both physical and cognitive deficits. By 2030, the prevalence
of stroke will increase by more than 20% over 2012 and the
direct medical costs are projected to reach $184.1 billion, which
is a great challenge to human society and healthcare system
(Mozaffarian et al., 2016). The situation is much worse in China,
where stroke is the leading cause of death (Wang H. et al.,
2016). Ischemic stroke is caused by the blockage of an artery
in the brain, accounting for approximately 87% of stroke cases,
which contributes to the major portion of death and post-stroke
disability in patients (Mozaffarian et al., 2016). In addition to
acute brain damage, stroke significantly increases the risk of
neurodegenerative diseases, such as Alzheimer’s disease (Wu
et al., 2014). However, current treatments are only limited to
thrombolytic therapy within an extremely narrow time window.
Therefore, it is urgent to develop novel therapeutic approaches
for stroke treatment.
Mechanisms of Cell Death in Ischemic
Stroke
Depending on the severity of lack of blood supply, the ischemic
territory consists of the ischemic core and penumbra, which
are respectively characterized by acute and delayed cell death,
necrosis and apoptosis (Lipton, 1999; Lo, 2008). Ischemic core,
the center area of the ischemic territory, is caused by an acute
blood reduction to less than 15%, while ischemic penumbra,
the surrounding area of the core, has a higher blood supply.
Necrosis occurs within minutes after stroke, thus, cells within
the ischemic core cannot be rescued. However, cells in the
penumbra experience less severe blood reduction and may
undergo apoptosis (Lipton, 1999; Lo, 2008). Although cells in the
penumbra are vulnerable, their death is salvageable by proper
intervention, suggesting that preventing penumbra cell death
is the key to improve the recovery from and the prognosis of
ischemic stroke. During acute ischemia, the diffusion of toxic
contents released from dead cells in the core region triggers
apoptotic responses. In addition, ischemia/reperfusion injury
contributes to the apoptosis of penumbral cells by a number of
molecular mechanisms, such as oxidative stress, inflammatory
response, endoplasmic reticulum (ER) stress and abnormal
protein degradation (Moskowitz et al., 2010; Zhang et al., 2014b).
Therefore, blocking the detrimental pathways has a therapeutic
potential to reduce penumbra cell death and improve stroke
recovery.
THE APELINERGIC SYSTEM—APELIN
AND APLNR
Apelin
The apelin (APLN) gene, located on chromosome Xq25, spans
9698bp, consisting of three exons and two introns. It encodes
the preproapelin of 77 amino acids. Various mature peptides
are derived from the 55 amino-acid propeptide, ranging from
13–36 amino acids. The mature peptides are highly conserved
between species. In particular, the C-terminal 23 amino acids
are 100% homologous between human and rat, mouse or bovine.
Tatemoto et al. (1998) first identified apelin-36 in vivo and
predicted it can be further processed to apelin-17 and apelin-13
with 17 and 13 amino acids, respectively. In addition, the
shorter C-terminal peptides, apelin-13 and its pyroglutamate-
modified form Pyr-apelin-13, have higher activity compared
with apelin-36 (Hosoya et al., 2000). Mesmin et al. (2011)
identified 46 endogenous apelin peptides in bovine colostrums.
Apelin-13, the most active isoform, has been widely studied in
ischemia/reperfusion injury (Tao et al., 2011; Khaksari et al.,
2012; Yang et al., 2014, 2015; Chen et al., 2015; Li et al., 2016).
Although all apelin isoforms may function through the unique
APLNR, their tissue specificity, binding affinity to APLNR and
efficacy in APLNR recycling may lead to differential functions of
isoforms. However, the proapelin processing and the proteases
involved in the generation of apelin isoforms have received less
investigation. Recently, Shin et al. (2013) showed that proprotein
convertase subtilisin/kexin 3 (PCSK3) directly cleaves proapelin
to generate apelin-13.
Apelin is expressed in both brain and peripheral tissues
in human. In the brain, apelin is expressed in thalamus,
frontal cortex and hippocampus, while it is also expressed
in placenta, heart, lung and other peripheral tissues. The
expression of apelin is controlled at both transcriptional and
post-translational levels (Figure 1). First, multiple transcriptional
factors are involved in the transcriptional regulation of apelin,
such as Sp1 transcription factor (SP1), signal transducer and
activator of transcription 3 (STAT3), hypoxia inducible factor
1 alpha (HIF-1α), upstream transcription factor 1/upstream
transcription factor 2 (USF1/USF2) and activating transcription
factor 4 (ATF4; Wang et al., 2006; Han et al., 2008; Lv et al., 2013;
Jeong et al., 2014; He et al., 2015). Moreover, tumor necrosis
factor alpha (TNF-α) increases the expression of APLN mRNA
via phosphatidyl Inositol 3-kinase (PI3K) activation (Daviaud
et al., 2006). In addition, apelin has a high turnover rate,
with a half life of less than 8 min (Aydin et al., 2014; Juhl
et al., 2016). Two identified proteases, angiotensin-converting
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enzyme 2 (ACE2) and metalloprotease (NEP), are involved in
apelin proteolysis, which partially or fully inactivate the binding
activity of apelin to its receptor and contribute to its degradation
(Kalea and Batlle, 2010; McKinnie et al., 2016; Wang W. et al.,
2016).
APLNR
APLNR is the unique receptor of apelin, while apelin has
until recently been considered the only endogenous ligand of
APLNR. Recently, Chng et al. (2013) reported that elabela, also
named as apela or toddler, is another endogenous ligand of
APLNR in zebrafish, which is essential for early cardiovascular
development. However, the expression of elabela is restricted to
pluripotent cells and kidney in human (Wang et al., 2015).
The APLNR gene is located on chromosome 11q12, spanning
3877bp genomic DNA without introns. Human APLNR,
consisting of 380 amino acids, shares more than 90% amino
acid sequence homology to mouse and rat APLNR. It is widely
distributed in human tissues. In human brain, APLNR mRNA
is highly expressed in caudate nucleus, corpus callosum and
hippocampus (Matsumoto et al., 1996; Edinger et al., 1998;
Medhurst et al., 2003). Recently, its expression is also detected
in the cortex (Hansen et al., 2007). The aforementioned evidence
suggests that APLNR has important functions in multiple brain
regions, which has not been fully investigated. APLNR, a typical
G protein coupled receptor (GPCR), mainly mediates signal
transduction via Gα subunit (Gαi or Gαq) of heterotrimeric G
protein. For example, Gαi contributes to PI3K/serine/threonine
kinase (PI3K/AKT) activation and extracellular signal-regulated
kinase (ERK) activation, while Gαq contributes to phospholipase
C beta-protein kinase C (PLCβ-PKC) activation (Chapman et al.,
2014). In addition, it may mediate signal transduction through
a β-arrestin-dependent mechanism (Chapman et al., 2014).
However, the exact role of the β-arrestin-dependent pathway in
signal transduction remains elusive.
A number of transcription factors are implicated in the
regulation of APLNR transcription, as multiple functional
binding sites are located in the promoter region of the
APLNR gene, including SP1, HIF-1α, glucocorticoid receptor
and estrogen receptor (O’Carroll et al., 2006; Figure 1). Insulin is
also involved in the regulation of APLNR expression (Dray et al.,
2010). In addition, apelin deficiency reduces the level of APLNR
mRNA (Wang et al., 2009). Hypoxia promotes both apelin
and APLNR expression accompanying with HIF-1α induction,
suggesting that upregulation of APLNR may be mediated by
both apelin and/or HIF-1α (He et al., 2015). Moreover, APLNR
undergoes multiple post-translational modifications, including
glycosylation, phosphorylation and palmitoylation, which may
contribute to the alteration of APLNR at the protein level by
affecting its turnover rate (Figure 1; O’Carroll et al., 2013;
Chen et al., 2014). For example, the phosphorylation status of
regulator of calcineurin 1(RCAN1) has a significant effect on its
degradation rate (Genescà et al., 2003).
TEMPORAL EXPRESSION OF
APELIN/APLNR IN ISCHEMIC STROKE
Increased Expression of Apelin/APLNR
During the Ischemic Phase of Ischemic
Stroke
Ischemia/reperfusion injury occurs in both heart and brain,
accompanied by many common pathophysiological alterations.
Numerous in vitro and in vivo studies showed that the expression
of apelin and APLNR is altered by ischemia/reperfusion injury
via a number of mechanisms (Figure 2). First, hypoxia and
glucose deprivation, the major consequences of ischemia, are
implicated in the aberrant expression of apelin and APLNR. The
expression of apelin and APLNR is increased under hypoxic
conditions, which is mediated by the induction of HIF-1α
FIGURE 1 | The expression of apelin and apelin receptor (APLNR) is differentially regulated at transcriptional and post-translational levels.
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FIGURE 2 | Temporal expression of apelin/APLNR in ischemic stroke.
HIF-1α and SP1 transcription factor (SP1) contribute to the upregulation of
apelin/APLNR during the ischemic phase, while multiple mechanisms are
involved in the reduction of apelin/APLNR during the reperfusion phase.
(He et al., 2015). HIF-1α can functionally bind to hypoxia
response elements (HREs) within the promoter region of the
apelin and APLNR genes, leading to the upregulation of apelin
and APLNR (Ronkainen et al., 2007; He et al., 2015). In addition,
glucose deprivation upregulates apelin and APLNR expression
at early stages (Zhang et al., 2009). Moreover, the increase of
SP1 promotes apelin and APLNR expression in ischemic neurons
at the early stage, which may be mediated by HIF-1α induction
(Woo et al., 2012; O’Carroll et al., 2006; Yeh et al., 2011; Lv et al.,
2013). Consistently, the expression of both apelin and APLNR
is increased by ischemia in rat hearts (Atluri et al., 2007; Sheikh
et al., 2008).
Reduced Expression of Apelin/APLNR
During the Reperfusion Phase of Ischemic
Stroke
Recent studies indicate that the expression of apelin and APLNR
may be temporally regulated in ischemic stroke. The expression
of apelin and APLNR is only increased early after ischemia
in heart (Rastaldo et al., 2011). Although glucose deprivation
upregulates the expression of apelin and APLNR at early stages,
it significantly reduces apelin and APLNR expression at later
stages (Zhang et al., 2009). The later-stage reduction of apelin
and APLNR may be associated with a plethora of mechanisms
in ischemic stroke (Figure 2). For example, ER stress is a
major mechanism contributing to ischemia/reperfusion injury
in both heart and brain (Morimoto et al., 2007; Nakka et al.,
2010; Tao et al., 2011; Xin et al., 2014). However, it is only
activated at the reperfusion stage but not at the ischemic stage
in both heart and brain (Morimoto et al., 2007; Nakka et al.,
2010; Tao et al., 2011). ATF4, an important mediator of ER
stress, significantly reduces apelin expression via a p38 mitogen-
activated protein kinase (p38-MAPK) dependent pathway (Jeong
et al., 2014), suggesting that ER stress may contribute to the
reduction of apelin expression during the reperfusion phase
(Figure 2). Subsequently, APLNR may be downregulated by
apelin reduction (Wang et al., 2009). In addition, inflammatory
responses may be implicated in the regulation of apelin and
APLNR expression mediated by STAT3, as it directly regulates
the promoter activity of the apelin gene (Han et al., 2008; Liang
et al., 2016). Interestingly, STAT3 is only activated during the
reperfusion phase but not the ischemic phase. The inhibition of
STAT3 signaling dramatically improves the outcome of ischemic
stroke, suggesting that STAT3 may contribute to the reduction
of apelin expression during the reperfusion phase (Figure 2;
Li and Zhang, 2003; Yu et al., 2013). Moreover, the interplay
among oxidative stress, ER stress, autophagy and inflammatory
responses may be implicated in the temporal expression of apelin
and APLNR (Sheng et al., 2012; Mei et al., 2015).
Understanding the temporal expression of apelin/APLNR
is critical for defining the timing of treatment with apelin
or APLNR agonists. For example, Rastaldo et al. (2011)
reported that apelin can only reduce infarct size of heart when
it is administrated at the reperfusion phase. Therefore, the
temporal expression of apelin/APLNR in ischemic stroke and the
underlying mechanisms need to be further investigated, which
is crucial for the therapeutic application of apelin or APLNR
agonists to treat ischemic stroke.
PROTECTIVE EFFECTS OF APELIN/APLNR
IN ISCHEMIC STROKE AND THE
UNDERLYING MECHANISMS
Apelin/APLNR Inhibits Cell Death in
Ischemic Stroke
Accumulated evidence indicates that apelin/APLNR improves
the recovery from ischemic stroke by inhibiting cell death and
facilitating angiogenesis, which are mediated by the activation of
PI3K/AKT and ERKs signaling pathways, respectively (Figure 3;
Chuang et al., 2011; Tao et al., 2011; Gu et al., 2013; Wang
et al., 2013; Zhu et al., 2013; Yang et al., 2014; Chen et al.,
2015; Liu et al., 2015; Huang et al., 2016; Novakova et al., 2016;
Zou et al., 2016). Oxidative stress is a major mechanism of
ischemia/reperfusion injury, leading to cell death. Mitochondria-
derived oxidative stress is involved in ischemia/reperfusion
injury by causing an overload in reactive oxygen species
(ROS) and the increased ROS further promotes mitochondria
impairment, forming a vicious feedback loop. Blocking this
vicious cycle by suppressing oxidative stress is a major
mechanism of apelin/APLNR’s protective effects on ischemic
stroke (Figure 3). First, apelin reduces ischemia/reperfusion
injury-induced oxidative stress by increasing the activity of
antioxidant enzymes in kidneys, such as superoxide dismutase
(SOD), catalase (CAT) and glutathione peroxidase (GSH-Px)
(Bircan et al., 2016). Than et al. (2014) showed that apelin
promotes the expression of antioxidant enzymes via MAPK
kinase/ERK pathway in adipocytes. Moreover, apelin analogs
inhibit mitochondrial ROS generation in hearts (Pisarenko et al.,
2015). The aforementioned evidence suggests that the protective
effect apelin/APLNR on oxidative stress-induced cell death may
be mediated by suppressing ROS generation and promoting ROS
scavenging, which remains to be investigated.
Oxidative stress not only promotes cell death but also
contributes to the induction of inflammatory responses, which
is another mechanism contributing to cell death in ischemic
stroke. Apelin inhibits inflammatory response via reducing the
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FIGURE 3 | Apelin/APLNR improves the recovery from ischemic stroke by inhibiting cell death and facilitating angiogenesis via Gαi- dependent
mechanisms, while the role of β–arrestin-dependent pathways in ischemic stroke is unknown.
generation of inflammatory cytokines (Figure 3). For example,
apelin significantly reduces the expression of inflammatory
cytokines in rat brains, such as interleukin 1 beta (IL-1β), TNF-α
and intercellular adhesion molecule 1(ICAM-1), and inhibits cell
apoptosis in rats with ischemic stroke (Chen et al., 2015; Xin
et al., 2015; Yan et al., 2015). Moreover, apelin markedly reduces
microglial activation and their recruitment to the ischemic
penumbra, which is associated with a decrease in cell death (Chen
et al., 2015).
Apelin can protect cells from apoptosis by preventing ER
stress, which is activated by ischemia/reperfusion injury in
both brain and heart (Figure 3; Morimoto et al., 2007; Nakka
et al., 2010; Tao et al., 2011; Xin et al., 2014). ER stress is
only activated at the reperfusion stage but not activated at the
ischemic stage, suggesting that administration of apelin during
the reperfusion stage may be effective in protecting cells from
ER stress-induced apoptosis (Morimoto et al., 2007; Nakka et al.,
2010; Tao et al., 2011). For example, Nakka et al. (2010) showed
that ER stress is activated around 3–6 h after reperfusion in rat
brains. Consistently, Tao et al. (2011) showed that ER stress
is activated 2 h after reperfusion in heart. Moreover, apelin
significantly reduces ER stress and infarct size via a PI3K/AKT-
dependent pathway (Tao et al., 2011). Importantly, apelin has
a long-term effect on the inhibition of ER stress, beyond 24 h
after reperfusion (Tao et al., 2011). However, the expression of
apelin is downregulated by ER stress (Jeong et al., 2014). The
aforementioned evidence indicates that apelin reduction and the
activation of ER stress may form a vicious feedback loop during
the reperfusion phase, similar to mitochondria-induced stress,
which potentiates ER stress-induced apoptosis. Thus, apelin
administration may block this vicious cycle to inhibit ER stress-
induced apoptosis in ischemic stroke.
Growing evidence indicates that the protective effect of apelin
on ischemia/reperfusion-induced apoptosis may be associated
with its role in the regulation of autophagy (Figure 3). First,
apelin is able to inhibit glucose deprivation-induced autophagy,
contributing to the protective effect on cardiomyocytes. This
effect is associated with the activation of PI3K/AKT/mechanistic
target of rapamycin (mTOR) pathway (Jiao et al., 2013).
In addition, apelin inhibits hypoxia-induced autophagy via
activating PI3K/AKT/mTOR pathway in muscle cells (Zhang
et al., 2014a). Moreover, apelin attenuates traumatic brain injury-
induced damage by suppressing autophagy (Bao et al., 2015).
Apelin/APLNR Promotes Angiogenesis in
Ischemic Stroke
Post-stroke angiogenesis has a beneficial effect on cell survival
and stroke recovery. Apelin not only protects cells from death
but also promotes angiogenesis against ischemic stroke and
improves stroke recovery (Chen et al., 2015; Huang et al.,
2016). Apelin facilitates angiogenesis and blood flow restoration,
which is dependent on an increase in vascular endothelial
growth factor- vascular endothelial growth factor receptor 2
(VEGF-VEGFR2) signaling. In addition, PI3K/AKT and ERKs
signaling pathways play a crucial role in apelin/APLNR-induced
angiogenesis in ischemic stroke, which may be mediated by
VEGF-VEGFR2 (Wang et al., 2013; Chen et al., 2015; Liu
et al., 2015; Novakova et al., 2016). Consistently, loss of apelin
impairs the angiogenesis and functional recovery (Wang et al.,
2013).
CONCLUSIONS AND PERSPECTIVES
The aforementioned evidence suggests that activating
apelin/APLNR system may be a potent approach for protecting
against ischemic stroke and improving recovery following an
ischemic event. However, several critical issues need to be
well resolved. First, the temporal expression of apelin/ APLNR
during ischemic stroke needs to be determined, as it is crucial
for deciding the timing of treatment with apelin or APLNR
agonists. Based on the alteration of apelin/APLNR expression in
ischemia/reperfusion injury of heart, application of apelin after
thrombolytic therapy may be an effective approach to protect
penumbra cells from apoptosis. Moreover, modified apelin or
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APLNR agonists with longer half life need to be developed,
as the half life of apelin is too short to be applied clinically.
Finally, non-invasive drug delivery methods need to be further
explored. As APLNR is widely expressed in peripheral tissues,
systematic delivery may generate more side effects. Thus, apelin
was administered through lateral ventricle injection in most
in vivo studies. However, this approach is not suitable for clinical
application. A recent study has applied intranasal delivery of
apelin for stroke treatment, shedding a light on exploiting
non-invasive apelin application to treat ischemic stroke (Chen
et al., 2015).
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